Recalled Medicines & supplements – Current GIS Alerts 2026
Found 713 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Temozolomide Sun
Stability testing showed that the product does not meet quality specification requirements for active substance content; the content is reduced below the lower acceptance limit, which affects the product’s effectiveness. Potential effects: reduced treatment efficacy, possible lack of therapeutic effect.
BOSS Energy Extra, Food supplement
Detected sildenafil, a medicinal substance prohibited in dietary supplements; consumption may pose health risks. Potential effects: cardiovascular disturbances, drug interactions (e.g. nitrates), complications in people with heart conditions.
Mebelin
Testing by the National Medicines Institute showed that the product does not meet quality requirements: release of mebeverine hydrochloride after 2, 8 and 12 hours was below the lower acceptance limit, which affects the effectiveness of the medicine. Potential effects: reduced effectiveness in treating intestinal complaints and possible worsening of disease symptoms.
Mebelin
Tests by the National Medicines Institute showed that the product does not meet the quality specification for mebeverine hydrochloride release – release after 2, 8 and 12 hours was below the lower acceptance limit, affecting the product’s effectiveness. Potential effects: lack or reduction of therapeutic efficacy, possible worsening of disease symptoms.
White Horse – dietary supplement
Detected sildenafil — an undeclared pharmacologically active substance in the product. Potential effects: drug interactions, cardiovascular disturbances, poisoning.
Ozempic
Keeping a falsified medicinal product on the market poses a direct and real threat to patients’ health and potentially life; there is no confirmation of the actual composition of the falsified product or its impact on pharmacological, immunological or metabolic action. Potential effects: poisoning, lack of treatment efficacy, severe complications.
Ozempic
Leaving a falsified medicinal product on the market poses a direct and real threat to patients’ health and potentially life; there is no confirmation of its actual composition or its effect on the medicine’s action. Potential effects: poisoning, lack of treatment efficacy, severe complications, life-threatening events.
Symibace
Stability studies showed a significant exceedance of the specification limit for impurity B, which poses a real and direct risk to patients’ health or life until the cause of the non-compliance is clarified. Potential effects: poisoning, serious adverse reactions, life-threatening events.
Ozempic
Leaving a falsified medicinal product on the market poses a direct and real threat to patients’ health and potentially to life. There is no confirmation of the actual composition or of the pharmacological, immunological or metabolic action of this product. Potential effects: poisoning, lack of treatment efficacy, severe complications, unpredictable reactions.
Ozempic
Leaving a falsified medicinal product on the market poses a direct and real threat to patients’ health and potentially life; the unknown composition and pharmacological action make its impact on the patient unpredictable. Potential effects: poisoning, lack of treatment efficacy, severe complications.
Ozempic
The falsified medicinal product with unknown composition poses a direct and real threat to health and potentially also to patients’ lives; its pharmacological, immunological or metabolic effects cannot be predicted. Potential effects: poisoning, lack of therapeutic efficacy, severe complications, allergic reactions or other unpredictable adverse effects.
Ozempic
Keeping the falsified medicinal product on the market poses a direct threat to patients’ health and potentially life, because there is no confirmation of the actual composition of the medicine and its impact on pharmacological, immunological or metabolic action cannot be predicted. Potential effects: poisoning, lack of efficacy, severe complications.
Ozempic
Keeping a falsified medicinal product on the market poses a direct and real threat to health and potentially also to patients’ lives; the lack of confirmed composition makes it impossible to predict its effect on pharmacological action and treatment safety. Potential effects: poisoning, lack of treatment efficacy, serious adverse reactions.
Symibace
Stability studies showed a significantly exceeded content of impurity B; the authority indicated that any exceedance of specification limits constitutes a real and direct threat to patients’ health or life. Potential effects: poisoning, serious adverse reactions, life-threatening events.
Ozempic
Keeping on the market a medicinal product for which falsification has been confirmed poses a direct and real threat to patients’ health and potentially life; there is no confirmation of the actual composition of the falsified product or its impact on the medicine’s effect. Potencjalne skutki: poisoning, lack of treatment efficacy, unpredictable adverse reactions.
Dexamytrex
Unidentified microbiological contamination of the active substance (gentamicin sulfate) was detected, posing a real and direct risk to patients and potentially adversely affecting the efficacy and safety of use of the eye ointment. Potential effects: eye infections, infectious complications, reduced treatment effectiveness.
Dexamytrex
Unidentified microbiological contamination of the active substance (gentamicin sulfate) may have negative effects on the efficacy and safety of using the eye ointment and constitutes a real and direct risk for patients using the product. Potential effects: eye infections, lack of treatment efficacy, inflammatory complications or damage to ocular tissues.
Antinervinum
A bottle of the medicinal product Antinervinum (batch 211001, expiry 10.2023) was located inside the supplement packaging, creating a risk of accidental ingestion of the medicine instead of the supplement. Potential effects: adverse reactions, interactions, or unintended drug exposure.
Levosimendan Kabi
Contamination with particles visible to the naked eye was found in the concentrate for solution for infusion, indicating a serious quality non-compliance of the product. Potential effects: thromboembolic and inflammatory complications, vascular damage, severe adverse effects after intravenous administration.
Egoropal
The product does not meet quality requirements due to a negative test result for the particle size analysis parameter, which is critical for the safety and efficacy of an injectable suspension. Potencjalne skutki: lack of treatment efficacy, adverse reactions, complications after injection.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.